Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 8/20 | 0.45 |
| ▸ | RARB | P10826 | 8/20 | 0.43 |
| ▸ | RARA | P10276 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6527017 | 0.93 | MMP12 (0.40) | S1PR1S1PR2RARBRARAMEN1 | |
| SCHEMBL6532172 | 0.86 | LTA4H (0.42) | — | |
| SCHEMBL6527581 | 0.85 | MMP12 (0.36) | S1PR1S1PR2RARBMMP12 | |
| SCHEMBL6530174 | 0.85 | LMNA (0.39) | S1PR1S1PR2RARBS1PR3S1PR4 | |
| SCHEMBL6529353 | 0.83 | S1PR2 (0.34) | S1PR1S1PR2S1PR3S1PR4MMP12 | |
| SCHEMBL6529532 | 0.83 | S1PR1 (0.44) | S1PR1S1PR2RARBRARAS1PR3 | |
| SCHEMBL6530119 | 0.83 | S1PR1 (0.44) | S1PR1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6529512 | 0.82 | MMP12 (0.40) | MMP12 | |
| SCHEMBL6500407 | 0.82 | ACACB (0.43) | MAPTMMP12 | |
| SCHEMBL6529005 | 0.82 | PTPN11 (0.40) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | claimed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005014525-A2 | BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY | MITSUBISHI PHARMA CORPORATION (JP) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | S1PR1 438/4885S1PR2 746/4885RARB 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.